MedTrace Logo

Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease

NCT01130597 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2021-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the feasibility of individualized titration of patiromer according to serum potassium. This study also assessed the safety and tolerability of patiromer and the effects of patiromer on serum potassium in heart failure (HF) participants with chronic kidney disease (CKD).

Conditions

Interventions

DRUG

patiromer

Active investigational drug

DRUG

spironolactone

Sponsors & Collaborators

  • Relypsa, Inc.

    lead INDUSTRY

Principal Investigators

  • Director Clinical Operations · Relypsa, Inc.

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Georgia
  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01130597 on ClinicalTrials.gov